S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$18.77
+0.11 (+0.59%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.51
$18.80
50-Day Range
$16.30
$18.66
52-Week Range
$14.87
$23.40
Volume
1.81 million shs
Average Volume
3.29 million shs
Market Capitalization
$6.08 billion
P/E Ratio
32.93
Dividend Yield
N/A
Price Target
$26.00

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
38.5% Upside
$26.00 Price Target
Short Interest
Healthy
2.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.50mentions of Exelixis in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$3.43 M Sold Last Quarter
Proj. Earnings Growth
52.24%
From $0.67 to $1.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.64 out of 5 stars

Medical Sector

3rd out of 1,002 stocks

Biological Products, Except Diagnostic Industry

1st out of 166 stocks


EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Neuroendocrine Tumor Treatment Market Share By 2031
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
3 Beaten-Down Stocks That Could Soar This Year
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
2 Stocks to Buy With Less Than $20
Exelixis: Q4 Earnings Snapshot
Exelixis Full Year 2022 Earnings: EPS Beats Expectations
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
2/07/2023
Today
3/28/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,223
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$26.00
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+38.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$182.28 million
Pretax Margin
14.55%

Debt

Sales & Book Value

Annual Sales
$1.61 billion
Cash Flow
$0.64 per share
Book Value
$7.68 per share

Miscellaneous

Free Float
314,688,000
Market Cap
$6.08 billion
Optionable
Optionable
Beta
0.69

Social Links


Key Executives

  • Michael M. MorrisseyMichael M. Morrissey
    President, Chief Executive Officer & Director
  • Christopher J. SennerChristopher J. Senner
    Chief Financial Officer & Executive Vice President
  • Dana T. Aftab
    Chief Scientific Officer & Executive VP-Discovery
  • Vicki L. Goodman
    Chief Medical Officer & Executive Vice President
  • Jeffrey J. HessekielJeffrey J. Hessekiel
    Secretary, Executive VP & General Counsel













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

9 Wall Street analysts have issued twelve-month price targets for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they anticipate the company's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2023?

Exelixis' stock was trading at $16.04 at the start of the year. Since then, EXEL shares have increased by 16.3% and is now trading at $18.66.
View the best growth stocks for 2023 here
.

Are investors shorting Exelixis?

Exelixis saw a decline in short interest in March. As of March 15th, there was short interest totaling 8,040,000 shares, a decline of 11.6% from the February 28th total of 9,090,000 shares. Based on an average daily volume of 3,120,000 shares, the days-to-cover ratio is presently 2.6 days.
View Exelixis' Short Interest
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EXEL earnings forecast
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.04. The biotechnology company had revenue of $423.92 million for the quarter, compared to analyst estimates of $418.71 million. Exelixis had a trailing twelve-month return on equity of 7.54% and a net margin of 11.31%. The business's revenue was down 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.29 earnings per share.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $415.00 million-$415.00 million, compared to the consensus revenue estimate of $414.83 million.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.62%), Price T Rowe Associates Inc. MD (2.05%), Meditor Group Ltd (2.05%), Point72 Asset Management L.P. (1.98%), Geode Capital Management LLC (1.41%) and Dimensional Fund Advisors LP (1.36%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $18.66.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.05 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 1,223 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 3/28/2023 by MarketBeat.com Staff